Pyrvinium clinical trials
How each study uses pyrvinium is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pyrvinium studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Pyrvinium
- 2
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
Thomas Jefferson University (1) · National University Hospital, Singapore (1) · Katherine Garman (1)
Studies
Open first, then newest update. How each study uses pyrvinium is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Use of Pyrvinium to Reverse Stomach Precancerous ConditionsNot yet recruitingPhase 2National University Hospital, SingaporeNCT06782048Written as PyrviniumHow we know
- REVerse Intestinal Metaplasia in the Stomach (REVISE)RecruitingPhase 2Katherine GarmanNCT06590454Written as PyrviniumHow we know
- A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic CancerActive, not recruitingPhase 1Thomas Jefferson UniversityNCT05055323Written as Pyrvinium PamoateHow we know
Codes
What other systems call pyrvinium · ClinicalTrials.gg INT002792
- MeSH (NLM) C024631pyrviniumConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6B9991FLU3PYRVINIUMConfirmed FDA, NLM, Wikidata
- RxNorm 35163Confirmed FDA, Wikidata
- Wikidata Q264039pyrvinium (cation)Confirmed FDA, NLM, Wikidata
- NCI Thesaurus C77330PyrviniumOne source FDA
- DrugBank DB06816One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C024631 | pyrvinium | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6B9991FLU3 | PYRVINIUM | Confirmed FDA, NLM, Wikidata |
| RxNorm | 35163 | — | Confirmed FDA, Wikidata |
| Wikidata | Q264039 | pyrvinium (cation) | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77330 | Pyrvinium | One source FDA |
| DrugBank | DB06816 | — | One source Wikidata |
Also registered as pyrvinium pamoate (UNII 310X6S84LW · RxNorm 55347).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.